Optimal cutoff value of the serum pepsinogen level for prediction of gastric cancer incidence: The Hisayama Study

Scandinavian Journal of Gastroenterology

Volumn 47, Issue 6, 2012, Pages 669-675

  Shikata, Kentaro ^a   Ninomiya, Toshiharu ^a   Yonemoto, Koji ^b   Ikeda, Fumie ^a   Hata, Jun ^a   Doi, Yasufumi ^a   Fukuhara, Masayo ^a   Matsumoto, Takayuki ^a   Iida, Mitsuo ^a   Kitazono, Takanari ^a   Kiyohara, Yutaka ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KURUME UNIVERSITY   (Japan)

Author keywords

cohort study; gastric cancer; serum pepsinogen

Indexed keywords

PEPSINOGEN I; PEPSINOGEN II;

ADULT; ARTICLE; CANCER INCIDENCE; CONTROLLED STUDY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; YOUDEN INDEX;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; JAPAN; MALE; MIDDLE AGED; PEPSINOGEN A; PEPSINOGEN C; PROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84860843467     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2012.658855     Document Type: Article

References (32)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Terry MB, Gaudet MM, Gammon MD. The epidemiology of gastric cancer. Semin Radiat Oncol 2002;12:111-27.
3. VerdecchiaA,MariottoA, GattaG,Bustamante-TeixeiraMT, AjikiW.Comparison of stomach cancer incidence and survival in four continents. Eur J Cancer 2003;39:1603-9.
4. Hosokawa O, Miyanaga T, Kaizaki Y, Hattori M, Dohden K, Ohta K, et al. Decreased death from gastric cancer by endoscopic screening: association with a population-based cancer registry. Scand J Gastroenterol 2008;43:1112-15.
5. Samloff IM. Immunologic studies of human group I pepsinogens. J Immunol 1971;106:962-8.
6. Samloff IM. Pepsinogens, pepsins, and pepsin inhibitors. Gastroenterology 1971;60:586-604.
7. Miki K, Ichinose M, Shimizu A, Huang SC, Oka H, Furihata C, et al. Serum pepsinogens as a screening test of extensive chronic gastritis. Gastroenterol Jpn 1987;22: 133-41.
8. Miki K, Ichinose M, Ishikawa KB, Yahagi N, Matsushima M, Kakei N, et al. Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer. Jpn J Cancer Res 1993;84:1086-90.
9. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992;52:6735-40.
10. Miki K,Morita M, Sasajima M, Hoshina R,Kanda E, Urita Y. Usefulness of gastric cancer screening using the serum pepsinogen test method. Am J Gastroenterol 2003;98:735-9.
11. Miki K, Urita Y. Using serum pepsinogens wisely in a clinical practice. J Dig Dis 2007;8:8-14.
12. Oishi Y, Kiyohara Y, Kubo M, Tanaka K, Tanizaki Y, Ninomiya T, et al. The serum pepsinogen test as a predictor of gastric cancer: the Hisayama Study. Am J Epidemiol 2006; 163:629-37.
13. Ohata H, Kitauchi S, Yoshimura N, Mugitani K, Iwane M, Nakamura H, et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 2004;109:138-43.
14. Yanaoka K, Oka M, Mukoubayashi C, Yoshimura N, Enomoto S, Iguchi M, et al. Cancer high-risk subjects identified by serum pepsinogen tests: outcomes after 10-year follow-up in asymptomatic middle-aged males. Cancer Epidemiol Biomarkers Prev 2008;17:838-45.
15. Watabe H, Mitsushima T, Yamaji Y, Okamoto M, Wada R, Kokubo T, et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 2005;54:764-8.
16. Ohmura T, Ueda K, Kiyohara Y, Kato I, Iwamoto H, Nakayama K, et al. Prevalence of type 2 (non-insulindependent) diabetes mellitus and impaired glucose tolerance in the Japanese general population: the Hisayama Study. Diabetologia 1993;36:1198-203.
17. Tanaka K, Kiyohara Y, Kato I, Matsumoto T, Yamagata H, Kubo M, et al. Incidence and prognosis of gastric cancer in a population based cohort survey: the Hisayama Study. Scand J Gastroenterol 2004;39:459-63.
18. Yamagata H, Kiyohara Y, Aoyagi K, Kato I, Iwamoto H, Nakayama K, et al. Impact of Helicobacter pylori infection on gastric cancer incidence in a general Japanese population: the Hisayama Study. Arch Intern Med 2000;160:1962-8.
19. SAS/STAT user's guide, version 8. Cary, NC: SAS Institute, Inc. 1999.
20. Youden WJ. Index for rating diagnostic tests. Cancer 1950; 3:32-5.
21. Perkins NJ, Schisterman EF. The inconsistency of "optimal" cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol 2006;163: 670-5.
22. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-45.
23. Miki K, Ichinose M, Kakei N, Yahagi N, Matsushima M, Tsukada S, et al. The clinical application of the serum pepsinogen I and II levels as a mass screening method for gastric cancer. Adv Exp Med Biol 1995;362:139-43.
24. Kitahara F, Kobayashi K, Sato T, Kojima Y, Araki T, Fujino MA. Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut 1999;44:693-7.
25. Hattori Y, Tashiro H, Kawamoto T, Kodama Y. Sensitivity and specificity of mass screening for gastric cancer using the measurement of serum pepsinogens. Jpn J Cancer Res 1995; 86:1210-15.
26. Dinis-Ribeiro M, Yamaki G, Miki K, Costa-Pereira A, Matsukawa M, Kurihara M. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. J Med Screen 2004;11:141-7.
27. Shikata K, Doi Y, Yonemoto K, Arima H, Ninomiya T, Kubo M, et al. Population-based prospective study of the combined influence of cigarette smoking and Helicobacter pylori infection on gastric cancer incidence: the Hisayama Study. Am J Epidemiol 2008;168:1409-15.
28. TsuganeS,SasazukiS.Dietandtheriskofgastric cancer: review of epidemiological evidence. Gastric Cancer 2007;10:75-83.
29. Correa P, Shiao YH. Phenotypic and genotypic events in gastric carcinogenesis. Cancer Res 1994;54:1941s-3s.
30. Kokkola A, Kosunen TU, Puolakkainen P, Sipponen P, Harkonen M, Laxen F, et al. Spontaneous disappearance of Helicobacter pylori antibodies in patients with advanced atrophic corpus gastritis. APMIS 2003;111:619-24.
31. Lambet R, Guilloux A, Oshima A, Pompe-kirn B, Bray F, Parkin M, et al. Incidence and mortality from stomach cancer in Japan, Slovenia, and the USA. Int J Cancer 2002;97:811-18.
32. Hisamichi S. Screening for gastric cancer. World J Surg 1989;13:31-7.